NeuroOne Medical Technologies Corp.

NeuroOne Medical Technologies develops minimally invasive diagnostic and therapeutic neurosurgical devices based on proprietary thin-film electrode technology. The company's primary platform enables high-definition neuronal recording and ablation for functional neurosurgery, with an initial focus on epilepsy and trigeminal neuralgia treatment. Core products include the OneRF® Radiofrequency Ablation System (FDA-cleared K231675 for functional neurosurgical procedures; K251243 for trigeminal nerve ablation), which uniquely performs both diagnostic mapping and therapeutic ablation using the same stereotactic electroencephalography (sEEG) electrode. The Evo® sEEG System (FDA-cleared K222404) provides temporary subsurface brain recording, monitoring, and stimulation, while the Evo® Cortical Electrodes (FDA-cleared K192764) offer surface brain recording with reduced immunological response and improved cable management. NeuroOne's flexible thin-film electrode platform is designed to provide higher-resolution neural signal acquisition compared to conventional rigid electrodes, potentially reducing infection risk and procedure complexity. The company is developing a comprehensive portfolio for neurological applications beyond epilepsy, working with leading neurosurgical centers including Mayo Clinic. All devices are subject to federal restriction to sale by or on the order of a physician.